Efficacy and safety of antibody-drug conjugates in the treatment of breast cancer：a meta-analysis
- VernacularTitle:ADC类药物治疗乳腺癌疗效与安全性的Meta分析
- Author:
Yinxue XU
1
;
Lei ZHANG
1
;
Xiwen QIAO
1
;
Xiaolan SHEN
1
;
Qian SHEN
1
;
Xuehui ZHANG
1
Author Information
1. Dept. of Pharmacy，the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University，Jiangsu Suzhou 215228，China
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates;
trastuzumab emtansine;
trastuzumab deruxtecan;
sacituzumab govitecan;
breast cancer
- From:
China Pharmacy
2023;34(20):2540-2544
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of antibody-drug conjugates （ADC） in the treatment of breast cancer， so as to provide an evidence-based reference for clinical medication. METHODS Retrieved from CNKI， Wanfang database， VIP， PubMed， the Cochrane Library， Embase， and Web of Science， randomized controlled trials （RCTs） about trastuzumab emtansine， trastuzumab deruxtecan and sacituzumab govitecan （trial group） versus chemotherapy or other anti-tumor drugs （control group）， were collected during the inception to April 2023. After screening the literature， extracting data， and evaluating the quality of the literature， a meta-analysis was conducted by using RevMan 5.4.1 software. RESULTS A total of 8 RCTs were included， with a total of 5 577 patients. The results of the meta-analysis showed that the progression-free survival （PFS） [HR＝0.76， 95%CI （0.69， 0.83）， P＜0.000 01]， overall survival （OS） [HR＝0.87， 95%CI （0.81， 0.93）， P＜0.000 1]， and clinical benefit rate （CBR） [OR＝2.70， 95%CI （1.15， 6.33）， P＝0.02] of the trial group were significantly higher than control group. There was no statistically significant difference in objective response rate （ORR） between the two groups [OR＝2.34， 95%CI （0.59， 9.33）， P＝0.23]. The results of subgroup analysis showed that the PFS of HER2-positive patients and HER2-negative patients， and the OS of HER2-positive patients in the trial group were significantly higher than control group （P＜0.05）. The incidence of anemia and increase of aspartic acid transaminase （AST） in the trial group was significantly higher than control group （P＜0.05）. The results of sensitivity analysis showed that the results obtained with PFS， OS， and ORR as indicators were relatively robust， while the results obtained with CBR as indicators lacked robustness. CONCLUSIONS ADC drugs have significant effects on breast cancer， but will increase the risk of anemia and elevated AST.
